IBRX Share Price Performance
US$2.53
-0.96 (-27.51%)
Price US$2.53
Share PriceUS$2.53
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 07
ImmunityBio, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 49 Fair Values set on narratives written by author
IBRX Community Narratives
There are no narratives available yet.
ImmunityBio, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.39
- Gross Margin
- 99.66%
- Net Profit Margin
- -648.57%
- Debt/Equity Ratio
- -140.2%
ImmunityBio, Inc. Competitors
Snowflake Analysis
About IBRX
- Founded
- n/a
- Employees
- 685
- CEO
- WebsiteView website
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.9% in the Information Technology sector. As for the past 12 months, the market is up 19%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›